[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594523":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":55,"collaborators":26,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":26,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":26,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":80,"overallStatus":84,"whyStopped":26,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Peking University Third Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"autologous platelet plasma group","ACTIVE_COMPARATOR","diabetic-related wounds after wound bed preparation are treated by the autologous platelet plasma",[13],"Drug: autologous platelet plasma",{"label":15,"type":16,"description":17,"interventionNames":18},"allogeneic platelet plasma group","EXPERIMENTAL","diabetic-related wounds after wound bed preparation are treated by the allogeneic platelet plasma",[19],"Drug: allogeneic platelet plasma",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","allogeneic platelet plasma","Al-PRP derived from healthy blood donors",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"autologous platelet plasma","Autologous platelet-rich plasma from the patient themselves",[9],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Long Zhang Executive Deputy Director, Medical Doctor","CONTACT","+86 010-82266699","liyunfeng1106@163.com",[38],{"facility":5,"status":26,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Beijing","Beijing Municipality","100191","China","CN",{"type":45,"coordinates":46},"Point",[47,48],116.39723,39.9075,{"lat":48,"lon":47},[51,53],{"name":52,"role":34,"phone":26,"phoneExt":26,"email":36},"Yunfeng Li, Medical Doctor",{"name":52,"role":54,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"type":54,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Long Zhang","Head of Wound Healing Center","100594523","phase-4-allogeneic-vs-autologous-prp-for-diabetic-wounds-in-renal-dysfunction-a-randomized-controlled-trial-100594523",false,"NCT07020559","Allogeneic vs Autologous PRP for Diabetic Wounds in Renal Dysfunction: a Randomized Controlled Trial","Comparing Allogeneic Versus Autologous Platelet-Rich Plasma for Diabetic Wound Healing in Patients With Renal Dysfunction：a Randomized Controlled Trial","Inclusion Criteria:\n\n1. The patient is aged 18-80 years old;\n2. Diagnosed as type 1 or type 2 diabetes according to the World Health Organization standard, blood sugar has been controlled before enrollment, and the level of Glycated hemoglobin HbA1c is less than 10%;\n3. Abnormal renal function defined as:\n\n   * Serum creatinine \\>106 μmol\u002FL (men) or \\>97 μmol\u002FL (women)\n   * AND eGFR \\\u003C90 mL\u002Fmin\u002F1.73m² (CKD-EPI) ；\n4. The patient has diabetes wounds with poor healing or prolonged healing need standard wound treatment;\n5. After preparing the wound bed, the condition for using platelet plasma to close the wound is met\\*;\n6. Voluntarily sign an informed consent form;\n\nExclusion Criteria:\n\n1. Blood glucose is out of control or not yet effectively controlled，;\n2. Severe diseases such as acute myocardial infarction, heart failure, hepatitis, shock, and respiratory failure have not been corrected yet;\n3. Active bleeding inside the wound, and routine basic treatment plans cannot be implemented；\n4. Uncontrolled systemic or disseminated infections;\n5. Patients with advanced malignant tumors;\n6. Pregnant or lactating women；\n7. The patient is unable to cooperate or has mental disorders;\n8. According to the judgment of the researchers, the patient has a clear and irremovable cause that affects wound healing, which is not suitable for this study or cannot comply with the requirements of this study.","ALL","18 Years","80 Years",{"count":69,"type":70},56,"ESTIMATED","INTERVENTIONAL",[73],"PHASE4","Diabetic wounds are difficult to heal. Autologous platelets in diabetic patients with renal insufficiency have poor function. Allogeneic platelet plasma has a promising application prospect. Comparing the efficacy and safety differences between allogeneic platelet plasma and autologous platelet plasma is of significant importance and value for the clinical application.",[76,77,78,79],"Diabetic Wounds","Platelet Rich Plasma","Allogeneic Blood Transfusions","Renal Dysfunction",[81,77,82,83],"Diabetic wounds","allogeneic blood","renal dysfunction","NOT_YET_RECRUITING","2025-08-23",{"date":87,"type":88},"2025-08-26","ACTUAL",{"date":90,"type":70},"2026-04",{"date":92,"type":70},"2028-05",{"name":5,"class":6},1]